What is it about?
Cytoprotector amifostine (AMI) was given in a dose of 50, 100 or 150 mg/kg ip in rats treated with several highly toxic doses of T-2 toxin. The best survival rate (24 h and 7 days after treatment) was obtained with AMI50 (50 mg/kg ip). After T-2 intoxication, a peak in the mean number of gastric lesions (petechiae and ulcerations) was reached on the third day (26.40 ± 6.24). Administration of AMI50 reduced, almost completely, the total number of gastric lesions in rats acutely poisoned by 0.5 LD50 T-2 (1.5 mg/kg sc), starting with day 1 after intoxication (5.60 ± 3.42).
Featured Image
Why is it important?
Our previously results have shown that amifostine produced a potent gastroprotective effect in rats poisoning by T-2 toxin. Since one of the mechanism by which inflammation can be attenuated is elimination of ROS and other free radicals and having in mind that the development of novel anti-inflammatory drugs is an important issue, we tested a hypothesis that amifostine has gastroprotective activity in an acute gastric injury in rats poisoned by T-2 toxin.
Perspectives
Our results support the hypothesis that AMI has a potent antiinflammatory activity in a model of acute gastric inflammation in rat poisoning by T-toxin. It might be a consequence of its inhibitory effects on PMNCs infiltration and free radical scavenging activity. AMI and its active metabolites may emerge as more effective therapeutic agent to counter gastric ulcer incidence. According to this fact, cytoprotector amifostine is a valuable candidate for further investigation as a drug for the treatment of various subacute disorders associated with T-2 toxin.
Research Professor Vesna Jaćević
National Poison Control Centre, Military Medical Academy & Medical Faculty, University of Defence, Belgrade, Sebia
Read the Original
This page is a summary of: Gastroprotective effects of amifostine in rats treated by T-2 toxin, Toxin Reviews, May 2017, Taylor & Francis,
DOI: 10.1080/15569543.2017.1329211.
You can read the full text:
Contributors
The following have contributed to this page
